Transcriptome analysis of Aristolactam BIII-treated monocytic cells (THP-1) (KAP230663)
To identify biomarkers that change when treated with the DYRK1A inhibitor, Aristolactam BIII, compared to PBS. To do this, It inhibited an immune response by treating human monocytic THP-1 cells with LPS.